Shares of Dr. Reddy's Laboratories Ltd. 500124 inched up 0.07% to 1,371.60 Indian rupees Thursday, on what proved to be an ...
The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...
Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...
Dr. Reddy’s Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate ...
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
Welcome to the Dr Reddys Stock Liveblog, your real-time source for the latest updates and comprehensive analysis on a ...
5d
Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY – Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $15.49 and traded ...
Semaglutide and Abatacept to offset revenue losses and 80% of EBITDA impact from the Revlimid patent expiry in 2026.
Dr Reddy's Laboratories Limited has announced the sale of its step-down wholly owned subsidiary, Dr Reddy's Laboratories ...
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active ...
Dr Reddy’s Laboratories ( (RDY) ) has provided an update.
Dr. Reddy's Laboratories Ltd. 500124 shares rallied 1.47% to 1,370.60 Indian rupees Wednesday, on what proved to be an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback